Episode 196: The COSMIC-313 Trial Cabo/Ipi/Nivo in First-Line Renal Cancer

By The Uromigos - Last Updated: September 14, 2022

Toni Choueiri describes the phase 3 pivotal COSMIC-313 trial that evaluates the combination of cabozantinib with nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Post Tags:UromigosUromigos-Kidney Cancer
Did you like this article?